Open an account

Inventiva SA

IVA · NYSE

$3.71+$0.11 (+3.06%)TodayMarket closed ·
Prev close $3.60

About IVA

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company employs 58 full-time employees The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Employees
73
Headquarters
Daix, Occitanie
Listed
Feb 15, 2017
Sector
Health Care
Industry
Biotechnology
Website
inventivapharma.com

IVA key statistics

Market cap
738.81M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.32M
Volume
4.71M
Open price
$3.55
High today
$3.76
Low today
$3.47
52 Week high
$7.98
52 Week low
$2.82

Inventiva SA (IVA) at a glance

As of Oct 23, 2026, Inventiva SA (IVA) shares are priced at $3.71, giving the company a market cap of 738.81M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.47 and $3.76. The current price is 6.9% above the day's low and 1.3% below its high.

Volume so far is 4.71M shares, above the average of 3.32M shares a day.

Over the past year Inventiva SA has ranged from $2.82 to $7.98, and now sits 17% of the way up that range.

The average analyst price target is $14.14, 281.1% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $14.14
Low
$7.60
Now
$3.71
High
$26.78

IVA news

  • Avi Kapoor

    Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

  • Avi Kapoor

    Pinterest, Destiny Tech100 And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

  • Avi Kapoor

    Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Insights into Inventiva's Upcoming Earnings

  • Avi Kapoor

    American Outdoor Brands Posts Downbeat Results, Joins Lululemon, Quanex Building And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • Avi Kapoor

    Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.